EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges

Jing Li, Shixiang Dong, Dongdong Hu, Wen Feng

Frontiers in Oncology · 09.07.2026 · 16

DOI: 10.3389/fonc.2026.1853596 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 09.07.2026. Verfasst von Jing Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The First People's Hospital of Lianyungang, Lianyungang, China. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer (EC) is one of the most common malignant tumors in women, and its incidence is rising continuously worldwide. According to recent global cancer statistics, there were about 417,000 new cases and 97,000 deaths from EC in 2020(1). The standard treatment for EC is hysterectomy, which undoubtedly deprives some young patients of their fertility. Fertility-sparing treatment (FST) for endometrial cancer allows these women to preserve fertility before undergoing standard treatment. Traditional fertility-sparing regimens are mainly based on progestin. However, in recent years, with the application of molecular classification, some studies have found that among patients undergoing FST, women with POLE mutations (POLE-mut) often have a higher complete remission (CR) rate, while those with P53 abnormal (P53abn) or mismatch repair deficiency (dMMR) have poor prognosis. Among them, patients with dMMR endometrial cancer seem to have a higher recurrence rate after achieving complete remission through progestin treatment. Currently, fertility-sparing treatment regimens for dMMR patients are being gradually studied, and immune checkpoint inhibitors (ICIs) may play a key role in the treatment.

Schlagwörter

Stichwörter der Autor:innen

endometrial cancerfertility spareimmune checkpoint inhibitorsmismatch repair deficiencymolecular classification

Autor:innen und Institutionen

  • Department of Gynecology, The First People's Hospital of Lianyungang, Lianyungang, China.
  • Department of Gynecology, The First People's Hospital of Lianyungang, Affiliated to Kangda College of Nanjing Medical University, Lianyungang, China.
  • Department of Gynecology, Lianyungang Hospital Affiliated to Xuzhou Medical University, Lianyungang, China.

Zitieren

APA

Li, J., Dong, S., Hu, D., & Feng, W. (2026). Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1853596

Vancouver

Li J, Dong S, Hu D, Feng W. Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1853596

BibTeX
@article{Li2026,
  author = {Li, Jing and Dong, Shixiang and Hu, Dongdong and Feng, Wen},
  title = {Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1853596}
}
Kostenlos starten →